Haemonetics (HAE) Tops Q3 EPS by 15c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $125.00 +3.92%
EPS Growth %: +1.6%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +1.6%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.81, $0.15 better than the analyst estimate of $0.66. Revenue for the quarter came in at $240 million versus the consensus estimate of $225.73 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enviri exits Deutsche Bahn contract, expects $19M net gain
- Contineum Therapeutics (CTNM) PT Lowered to $23 at Stifel
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
